CTA101

Phase 1Cell therapy

TThe First Affiliated Hospital with Nanjing Medical University

CTA101 is one of 90 biologic programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse Large B-Cell LymphomaActive, not recruiting

B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Diffuse Large B-Cell LymphomaPhase 1

Active, not recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

332 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

39 2

Rituxan

Gemzar

19 4

Gazyva

Roche

Phase 3

18 5

Eloxatin

Teva

Phase 3

17 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

68 7

Rayos

RRoxane Laboratories

Phase 3

57 8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

29 9

COLUMVI

Cytosar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Hematological Malignancy

NCT04227015

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma1 trial

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT04026100·9 enrolled

B-cell acute lymphoblastic leukemia1 trial

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

Unknown status·KKai Lin Xu; Jun Nian Zheng·Phase 1·NCT04154709·15 enrolled

Hematological Malignancy1 trial

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Recruiting·HHe Huang·Phase 1·NCT04227015·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CTA101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CTA101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CTA101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital with Nanjing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: TThe First Affiliated Hospital with Nanjing Medical University

CTA101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma1 trial

B-cell acute lymphoblastic leukemia1 trial

Hematological Malignancy1 trial

References

Drug Info

Quick Facts

Related News